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Abstract 
 
The modern debate about schizophrenia began over 100 years ago, with Kraepelin’s 
description of “dementia praecox”. Despite this, central aspects of the disease 
remain mysterious and the disease itself is still associated with a high probability of 
an enduring limitation of the patient’s quality of life. While several conceptions of 
schizophrenia exist and are still under discussion, at least a provisional consensus 
regarding a valid measure of schizophrenia seems to have been reached: The 
Positive and Negative Syndrome Scale (PANSS) quantifies the current state of a 
person with schizophrenia by combining 30 different schizophrenia-associated 
symptoms into a single scale value.  
Even though the scale is widely used and is the measure of choice in many clinical 
trials, its psychometric properties are still the reason for serious confusion. In many 
research papers, one important fact about the PANSS is overlooked: it is an interval 
scale and, therefore, straightforward calculations of proportions are not appropriate. 
In other words, calculating simple percentage changes is incorrect and a prior scale 
correction is required. These kinds of calculations often appear in conjunction with 
responder analyses, as the definition of response is usually based on a predefined 
cut-off in terms of percent scale change. Two of the presented papers of this thesis 
are dealing with this urgent problem: using real data as well as simulated data sets, 
it is shown that ignoring the scale level of the PANSS can, in many cases, even lead 
to false test decisions concerning an examined treatment effect. Furthermore, an 
analysis of the problem’s urgency with regard to academic discussions, performed 
by way of a systematic study of literature in the highest-ranked journals dealing 
with schizophrenia, showed that incorrect calculations are widespread in the 
literature and that there is a strong need for a general clarification. 
As incorrectly calculated percent changes might be a reason for the published low 
cut-offs of response, as e.g. 20% or 30% cut-offs, the third included article in this 
thesis analyzes the association of correctly calculated percent changes in the 
PANSS with a generally measured therapy response. An equipercentile linking of 
percent PANSS changes and the improvement item of the Clinical Global 
Impression Scale (CGI) confirmed the choice of a considerably higher response cut-
off of 50%. 
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The combined conclusion of the three included articles is the emphasis on the need 
for a general methodological consensus in schizophrenia research. Valid and 
replicable research is only possible on the basis of generally accepted methods that 
rely on the correct application of scale theory in these studies. 
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Zusammenfassung 
 
Vor mehr als 100 Jahren fiel mit Kraepelins Beschreibung der sogenannten 
„Dementia Praecox“ der Startschuss für die moderne Schizophreniedebatte. Trotz 
dieser langen Zeitspanne bleibt diese Erkrankung in zentralen Punkten 
unverstanden und ist immer noch mit einer hohen Wahrscheinlichkeit dauerhafter 
Einschränkungen der Lebensqualität Erkrankter verbunden. Während aber auf der 
einen Seite verschiedene Schizophreniekonzepte nebeneinander existieren und 
diskutiert werden scheint es inzwischen zumindest einen vorläufigen Konsens über 
die Beantwortung der Frage zu geben, wie die Ausprägung der Erkrankung zu 
messen ist: Die „Positive and Negative Syndrome Scale“ (PANSS) quantifiziert den 
aktuellen Zustand eines schizophrenen Patienten durch das Zusammenfassen von 
30 verschiedenen, mit Schizophrenie assoziierten Symptomen zu einem Skalenwert.  
Aber obwohl die Skala weit verbreitet und das Messinstrument der Wahl in vielen 
klinischen Studien ist, sind ihre psychometrischen Eigenschaften immer noch der 
Grund für schwerwiegende Konfusionen. In vielen wissenschaftlichen Artikeln wird 
eine wichtige Eigenschaft der PANSS übersehen: sie ist eine Intervallskala und als 
solche ungeeignet für die Berechnung von Proportionen. Mit anderen Worten: das 
simple Berechnen von prozentualen Veränderungen ist falsch, es bedarf hier einer 
zusätzlichen Korrektur. Diese prozentualen Veränderungen tauchen aber ihrerseits 
häufig im Zusammenhang mit Responder-Analysen auf, da die Definition von 
Response üblicherweise über eine a priori definierte prozentuale 
Skalenverbesserung erfolgt. Zwei der in dieser Dissertation dargestellten Artikel 
befassen sich direkt mit diesem gravierenden Problem: mithilfe von sowohl realen 
als auch simulierten Daten wird gezeigt, dass das Ignorieren des Skalenlevels der 
PANSS in vielen Fällen sogar zu falschen Testentscheidungen bezüglich eines 
vermuteten Behandlungseffekts führen kann. Eine anschließende systematische 
Literatursuche in den höchstrangigen Schizophrenie-Journalen zeigt, dass der 
Berechnungsfehler in der Literatur weitverbreitet ist, es also generell großen 
Klärungsbedarf bei diesem Thema zu geben scheint. 
Falsch berechnete prozentuale Veränderungen ihrerseits könnten mit ein Grund 
sein für gebräuchliche, niedrige Schwellenwerte für Response, wie beispielsweise 
20%- oder 30%-Kriterien, weshalb sich der dritte Artikel dieser Arbeit mit dem 
Zusammenhang von, richtig berechneten, prozentualen Veränderungen der PANSS 
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mit einem allgemein gemessenen Therapieresponse befasst. Eine equiperzentil 
Linking Analyse von prozentualen PANSS-Veränderungen mit dem Verbesserungs-
Item der „Clinical Global Impression Scale“ (CGI) bestätigt die Wahl eines 
wesentlich höheren Schwellenwertes von 50%. 
Zusammengefasst betonen die drei dargestellten Artikel die Notwendigkeit eines 
generellen methodologischen Konsensus in der Schizophrenieforschung. Valide und 
reliable Forschung ist nur möglich auf der Basis generell akzeptierter Methoden, 
die sich ihrerseits auf die korrekte Anwendung skalentheoretischer Erkenntnisse 
stützen. 
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Introduction 
 
Schizophrenia is a severe mental disease that is characterized by different 
psychopathological symptoms like disturbance of the affect, difficulty thinking or 
dysfunction of perception. Its lifetime prevalence is estimated at around 1% [31]. 
Even though there has been an ongoing debate about schizophrenia for over 100 
years, its aetiology, course, and treatment are still not completely understood.  
Several different theories offer explanatory approaches for the emergence of 
schizophrenic symptoms. Twin studies have shown that the risk of illness increases 
with closer biological relationship to diseased persons, which suggests a genetic 
predisposition to schizophrenia. Further explanatory approaches consider abnormal 
dopamine activities to be an important factor for this disease [13], others describe 
early viral or bacterial infections [9] and also perinatal complications [10] as 
potential risk factors. Modern treatment strategies refer to the dopamine approach 
since they are based on medical applications in terms of antipsychotics, which 
influence the dopamine metabolism. Despite these treatment regimens, the course 
of schizophrenia is heterogeneous, with some patients still suffering from a poor 
prognosis and a high probability of enduring limitations in their quality of life. 
One reason for this might be the heterogeneity of its pathophysiological 
underpinnings and clinical characteristics, ranging from blunted affect and social 
withdrawal to disturbances in complex thinking to the highly conspicuous 
symptoms of delusions or hallucinations. This wide variety of symptoms might have 
contributed to the initial difficulties of an adequate definition of this illness. 
Kraepelin offered a first description in 1899 [21] by combining several typical 
courses of the disease, beginning in adolescence with the onset of intellectual 
decline and ending with an early stage of dementia leading into an entity disease 
called “dementia praecox” (early dementia). This definition included an essential 
early start of the disease as well as a mental deterioration, which, as we now know, 
are not necessarily both present. Nevertheless, it is to Kraepelin’s merit that these 
symptoms were distinguished from affective disorders or, in Kraepelin’s words, 
from manic-depressive illness. As it was clear that Kraepelin’s conception was not 
wide enough, his first attempt of describing this mental illness was replaced by a 
new definition. In 1911, Bleuler published his monograph “Dementia praecox oder 
Gruppe der Schizophrenien,” [7] where he broadened the definition by describing 
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basic symptoms (affect, association, ambivalence, autism and others) and several 
accessory symptoms (like hallucinations, delusion or catatonia). He introduced the 
term “schizophrenia” as a description of a group of mental diseases with these 
symptoms. 
Schneider [40] added a new point of view on schizophrenia by introducing the 
differentiation between first- and second-rank symptoms. In particular, his careful 
perception of psychiatric diagnoses still influences the debate: if aetiology and 
pathogenesis of a disease remain unknown, as is the case in schizophrenia, he 
claimed that one cannot talk about differential diagnoses but only about differential 
typologies. 
This point of view contributed to the modern operationalized diagnostics used in 
ICD-10 and DSM-IV. Here, schizophrenia is classified by a long list of phenotypical 
symptoms including the symptoms described by Bleuler as well as those described 
by Schneider. Both ICD-10 and DSM-IV classify schizophrenia into diverse subtypes 
such as the paranoid or the catatonic subtype by combining special groups of 
symptoms. This classification is solely descriptive without any prognostic capacity. 
This prognostic capacity is assigned to the conception from Crow [12] and his 
distinction between type-I and type-II Schizophrenia. The basis of this classification 
is the distinction between positive and negative symptoms. Positive symptoms are 
symptoms with productive character such as hallucinations, delusions or bizarre 
behaviour and are supposed to be dominant in type-I. Type-II is dominated by 
negative symptoms. These symptoms are characterized by the absence of normal 
experiences and appear, for example, in deficits of the affect, of thinking and 
communication or in decreased motivation. This classification allows a connection 
between diagnosis and prognosis, as negative symptoms are supposed to be 
associated with poorer response to antipsychotics: type-I is therefore called acute 
schizophrenia, type-II chronic schizophrenia. Although this simplifying concept of 
type-I and type-II schizophrenia could not be validated [31], the distinction in 
positive and negative symptoms plays a central role in modern discussion and is 
part of important psychiatric rating scales.  
These scales are of essential interest in schizophrenia research: in psychiatric 
research in general, no biological markers exist offering an objective measure of 
disease severity. Therefore, other measures are needed to obtain as precise of an 
impression of a patient’s condition as possible. By describing the intensity of 
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relevant symptoms with a combining scale, value rating scales offer a good insight 
into a patient’s current situation with regard to his symptoms and allow for 
comparison both between different patients and different time periods for a single 
patient. Comparing the scale value courses between differently treated patient 
samples allows a substantiated efficacy assessment with regard to the applied 
treatment strategies.  
Particularly in approval studies of new medications, these assessments are of 
essential importance as they are the basis for the approval of a new treatment: only 
medications showing significant positive effects according to the applied psychiatric 
rating scales are supposed to offer a benefit to patients. A central requirement in 
this context is a satisfying external validity, which means the assumption that the 
applied scales adequately measure the patients’ statuses: different score values 
should represent patients’ states that are actually different and a score-change in 
time should correctly indicate a shift in a single patient’s status. The condition for 
this requirement is generally a solid and comprehensible scale validation based on 
classical test or modern item response theory and, especially, an extensive rater 
training yielding a correct and comparable scale application by individual raters. 
Examples of common rating scales used in schizophrenia are scales measuring the 
global functioning of patients like the Global Assessment Scale of Functioning (GAF, 
[1]) or those measuring a patient’s quality of life such as the Lancashire Quality of 
Life Profile (LQLP, [43]). The first scales measuring particularly positive and 
negative symptoms were the Scale for the Assessment of Negative Symptoms [2]  
and the  Scale  for  the  Assessment  of  Positive Symptoms [3]. In 1987, Kay et al. 
developed the Positive and Negative Syndrome Scale [17] by combining two 
established rating systems, the Brief Psychiatric Rating Scale (BPRS, [36]) and the 
Psychopathology Rating Schedule (PRS, [41]) into a single rating instrument. Their 
aim was to develop a standardized scale, which measures both positive and negative 
symptoms with the same priority, reacts sensitively to drug-related changes, and 
includes a measure of general psychopathology. Their development has become a 
complete success and this scale is likely used the most in current schizophrenia 
research. 
The PANSS consists of 30 items measuring specific symptoms, each item ranging 
from 1 (absent) to 7 (extreme). A total score is built by simply adding up the single 
items. These psychometric properties are the background for this current research. 
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The scale is based on a formalized psychiatric interview taking approximately 45 
minutes and requiring an accurate rater training to reach a satisfying level of 
reliability. A detailed manual [16,18] offers a broad description of the aim of this 
instrument and of the interview procedure, including information about its 
beneficial psychometrical properties. 
As indicated by the name, a special focus lays on the measurement of positive and 
negative symptoms: there are seven items measuring positive symptoms, seven for 
negative symptoms and 16 items corresponding to general symptoms. The positive 
symptoms comprise of delusions, conceptual disorganization, hallucinations, 
hyperactivity, grandiosity, suspiciousness and hostility and together form a positive 
subscale. In the negative items, the symptoms blunted affect, emotional withdrawal, 
poor rapport, apathetic social withdrawal, difficulty in abstract thinking, lack of 
spontaneity and stereotyped thinking are included. Together, they form the negative 
subscale. A bipolar composite scale can be formed by subtracting the negative from 
the positive score. The 16 general and respectively global items measure symptoms 
like anxiety, tension, mannerism, unusual thought contents or disorientation. 
Since its initiation, several post validity studies using factor analytical methods 
empirically identified a five-factor structure of the scale (e.g. [6], [28], [26]) 
including a negative factor, a positive factor, a disorganized factor, an anxiety or 
depression factor and an excitement factor. 
The PANSS total as well as its subscales and factors serve as a measurement of the 
patient’s current symptom status. While, for example, the PANSS positive subscale 
tells something about the level of psychotic symptoms, the PANSS total score is 
supposed to measure the patient’s condition with respect to the illness in general. 
Accordingly, the PANSS is used in clinical studies to describe the 
psychopathological condition of a patient or to quantify effects of special 
treatments. Several possibilities for the quantification of a treatment effect are 
established: unadjusted before-after differences in scale values can be used as a 
measure of effect, as well as proportional values, where this difference has been 
adjusted to the scale value before treatment. Dichotomous outcomes are also 
established: they define an aim in terms of a PANSS measure that describes a 
successful treatment. A common outcome domain are the widely-used consensus 
criteria for remission by Andreasen et al. [4], which describe a remitted status of a 
patient’s schizophrenia disorder by focussing on eight PANSS items measuring core 
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symptoms of schizophrenia. Another important outcome definition is the response 
criterion, which is based on the percent change in the scale over time. Patients who 
reach at least a pre-specified proportional PANSS-change during treatment are 
classified as responders. The cut-off for this criterion is often set to 50%, but other 
levels are also common. 
Obviously, percent changes (PC) play an important role in PANSS-measured 
schizophrenia studies, either as continuous effect-measures or as a basis for the 
classification of treatment responders. In this context, unfortunately, one important 
characteristic of the scale is often overlooked. This point is the topic of the first 
paper presented in this thesis [34] and is described in the following. 
Because all items of the scale range from one to seven, the minimum possible value 
of the total score is 30 for patients with no symptoms at all. This artificial base-level 
of 30 points leads to the fact that the PANSS is an interval scale, where 
straightforward calculations of ratios are not appropriate, meaning that a score 
reduction from 80 to 40 points does not represent a 50% reduction! In other words, 
if, for example, the PANSS score of a patient is 50 points at baseline and 30 points 
at endpoint the patient has obviously responded completely, as he has lost all 
relevant (i.e. PANSS-measured) symptoms. However, with a naïve PC calculation 
( 4.0
50
)3050(
=
−
) he would only reach a percentage improvement of 40%, not even 
fulfilling the 50% response cut-off.  
The reason for this gap lays in the absence of a natural zero-point of the scale, 
which is also the key for a solution of this problem: subtracting the potential 
minimum of 30 points lets the PANSS start at zero and changes the scale level from 
an interval to a ratio scale. With this rescaled PANSS, calculations of PC are 
appropriate and lead in the described example to a 100% reduction ( 1)3050(
)3050(
=
−
−
). 
It is easy to see that results not based on proportions are not affected at all by this 
rescaling procedure, as absolute differences stay the same regardless of the 
possible scale minimum. 
Based on this score characteristic and the fact that it is often overlooked, the paper 
tries to find an answer to the question of the relevance of correct PC calculations: is 
it possible that study results differ according to their PC calculation method? And if 
so, in which direction do they differ? To find an answer, real data from a naturalistic 
trial by the German research network on schizophrenia [44] have been used as well 
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as data from a simulation study. In each study, both ways of calculating PC have 
been performed and their results concerning a test on group difference have been 
compared.  
Indeed, serious differences have been found in the real as well as in the simulated 
data with, in part, over 50% difference in test decisions, i.e. tests where a 
significant effect was found with one method while the same data and the same test 
using differently-calculated PC values yielded a non-significant effect with the other 
method.  
The central point of this paper is the fact that results of both methods, with or 
without rescaling, are, strictly speaking, incomparable with each other and that a 
consensus in the psychiatric community about a solution to this problem is needed. 
Indeed, several solutions seem possible and are discussed in the article. In a 
comment to this paper, Leucht et al. [25] proposed the radical solution of a strictly 
rescaled version of the PANSS with each item going from zero to six instead of one 
to seven. However, the probability of success for this proposal depends on the 
awareness of the problem in the psychiatric community. While the paper finds an 
answer to the question about the possible impact of incorrect PC calculation on the 
result of a study, the dimension of this problem in general, i.e., its prevalence in the 
literature remains unclear. It may be negligible if only a small minority of authors 
use uncorrected score values while the larger majority rescales the PANSS before 
calculating PCs. On the other hand, a widespread prevalence of incorrectly-
computed PCs would mean that a good portion of published results need to be 
recalculated before they can be compared to other results.  
In the first paper of this thesis, some examples of articles with obviously incorrect 
calculations are shown, even including an application study, in addition to a number 
of papers with correct calculation. These examples were all found by a more or less 
unstructured literature study and therefore do not provide a representative profile of 
scientific literature using PANSS PCs. To get a more meaningful impression of the 
problem’s prevalence, a systematic study of the literature is needed. This was the 
motivation for the next paper, which includes the results of such a study [35]. 
For this paper, articles from the 10 highest-ranked psychiatric journals, excluding 
those focusing on topics not related to the PANSS and schizophrenia, were found by 
a systematic literature search using the PRISMA statement [30]. The methods of PC 
calculation in the papers were analysed with regard to the presence or lack of 
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rescaling and these results associated to the prominence of PC in the respective 
articles. 
The research in January 2011 ultimately confirmed the apprehension that most of 
the articles using PANSS PC values did not use the score correction. Even in articles 
with PANSS PC as a primary outcome, this outcome measure was frequently 
calculated incorrectly. The results of this literature study highlight the dimension of 
the problem and the urge for a general consensus in the psychiatric community 
about how to handle it.  
Besides resulting in possibly incorrect test decisions, the incorrect or unclear PC 
calculation method means that two researchers might not be talking about the same 
thing if they discuss PANSS-measured outcomes. While one researcher observes 
high, correctly-calculated response rates using a 50%-criterion, another author 
calculates far lower response rates with the same criterion but without rescaling. In 
the comment on the prior paper, Leucht et al. [25] express the assumption that 
incorrect calculations might partly be the reason for low response rates and low cut-
offs in studies. 
Indeed, many different response cut-offs are established and widely used: a 20%-
criterion is common (e.g. [37], [33]) as well as a 50% criterion (e.g. [38], [32]), and 
there are also examples for 30% (e.g. [19], [29]) and 40% criteria (e.g. [14]). 
Leucht et al. [22] proposed using a 50% cut-off for acutely-ill and a 25% cut-off for 
treatment-resistant populations. Furthermore, the PANSS reduction should be 
presented in a table offering the results of different cut-offs in 25%-steps to provide 
a comprehensive overview and to evaluate whether the effects were consistent. The 
European Medicines Agency (EMEA) accepts responder definitions above a 30%-
criterion and recommends the presentation of additional results with alternative 
criteria for sensitivity analyses [11]. 
Nevertheless, it seems important to get an idea of what different cut-offs stand for. 
Again, Leucht et al. offered an initial answer to the question “What does the PANSS 
mean?” [24]. Using an equipercentile linking approach, they linked PANSS values to 
concurrently rated values of the Clinical Global Impression Scale [15], which 
describes a patient’s overall clinical state. The CGI consists of two main subscales, 
each ranging from one (the best) to seven (the worst), which measure the patient’s 
current state (CGI-severity) and the patient’s state improvement since the beginning 
of a study (CGI-improvement). It is universally applicable for measuring the status of 
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depressed patients as well as the status of schizophrenic patients and is therefore, 
and because of its quick handling, a widely used rating instrument for measuring 
treatment effect.  
Linking the PANSS and the CGI provides, in simple terms, a kind of translation of 
special PANSS (improvement-) values into the graduation of the CGI, which is 
intuitively easier to understand. The idea of equipercentile linking is to find the 
scores for two scales that correspond to each other with regard to their percentile 
rankings. The procedure is described in detail in Kolen and Brennan [20]. 
Applying equipercentile linking, Leucht et al. found a PANSS PC of around 50% 
being associated with a CGI-improvement of 2, which means “much improved” and 
would be a reasonable choice for a response criterion. In a replication analysis, 
Levine et al. [27] confirmed this association with a PANSS PC of 45-49% fitting to a 
CGI-I of 2. 
While these linking analyses were based on data from several, international clinical 
trials, Schennach-Wolff et al. [39] aimed to replicate and validate the results in an 
own study using data from the aforementioned naturalistic trial of the German 
research network on schizophrenia [44]. This article is the third paper included in 
this thesis. It consists of three different linking analyses: one between PANSS total 
and CGI-severity, a second between PANSS PC and CGI-improvement and a third 
between PANSS absolute change again with CGI-improvement. All of these analyses 
were performed during different time periods.  
While the results show a huge difference to the results from Leucht et al. and Levine 
et al. in the linking of PANSS total and CGI-severity, the analyses concerning PANSS 
PC and CGI-improvement are more similar: a CGI value of 2 (much improved) fits 
very well to a PANSS improvement of 50%. Linking the absolute PANSS change 
with the CGI-improvement, a moderately convex shape of the linking graphs 
appears, which may be a sign of the fact already described by Leucht et al. [23], that 
CGI-improvement measures relative change more than absolute change. 
The most significant result of this paper with regard to the present thesis is the 
confirmation of a reasonable, high cut-off as response criterion: a 20% PANSS 
reduction refers to a CGI-improvement of 3, which only means “minimally 
improved” and therefore does not seem to be enough to classify a patient as a 
responder to a treatment. The correct choice for a cut-off in the sense of this linking 
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analysis would be a 50% reduction, fitting to a CGI-improvement of 2 (“much 
improved”). 
In summary, the necessity of appropriate definitions and methods in psychiatric 
research should continue to be emphasized. Moreover, even if it might be trivial to 
note, it is important to achieve a generally accepted consensus about what 
definitions and methods should be used. Discussions are needlessly complicated if 
two researchers think they are debating the same things, but indeed they are not. 
Therefore, a consensus must be reached about how to handle the PANSS in the 
future, i.e., if it should be rescaled and generally renamed, and also with regard to a 
universally valid response criterion for schizophrenic patients. 
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The design of the Positive and Negative Syndrome Scale
(PANSS) with item levels ranging from 1 to 7 leads to
the trivial result that the 30-item scale’s zero level (no
symptoms) is 30. This causes serious problems when ratios
are calculated which always implicitly depend on a natural
zero point (equals 0). Recent publications concerning effi-
cacy of antipsychotics correctly suggest a subtraction of 30
points to every PANSS before calculating percent change
(PC). Nevertheless, the traditional approach using uncor-
rected scores is still in common practice. This analysis aims
to clarify which approach is the most appropriate from
a statistical perspective.For analysis, data from a natural-
istic study on 400 patients with a schizophrenic spectrum
disorder and simulated data sets were used. While calcula-
tions concerning absolute score values and their differences
are not affected, considerable problems arise in calcula-
tions of PC and related response criteria. Even significance
levels of estimated treatment effects change, depending on
the structure of the data (eg, baseline symptom severity).
Using a PANSS version with items ranging from 0 to 6
would avoid such often neglected pitfalls.
Key words: scale level/minimum subtraction/percent
change/simulation study
Introduction
The Positive and Negative Syndrome Scale (PANSS1,2) is
one of the most common scales in clinical studies for
measuring symptom severity in patients with schizophre-
nia. Treatment effects relating the posttreatment score
(PANSS99) with the corresponding baselinemeasurement
(PANSS0) can be analyzed and compared. Various effect
measures have been discussed in statistical literature:
To¨rnqvist et al3 compare up to 10 ways of measuring
a relative difference resulting in the proposal of the log
chance and the log percentage, while Berry and Ayers4
showed the high power of symmetrized percent change
(PC) in statistical analyses. In the present article, we fo-
cus on the ordinary PC 100 3 (PANSS99  PANSS0)/
PANSS0 because it is commonly used in schizophrenia
research5 to indicate treatment effects: Response is typ-
ically defined as a distinct reduction level in terms of PC
in the total score which has to be reached (eg, see Leucht
et al,6 Marder and Meibach,7 Peuskens8). But regardless
of which of the above-mentioned measures is used, its
proper calculation confronts researchers with a severe
pitfall.
The PANSS is an interval scale where calculating ratios
is not appropriate due to the lack of a natural zero point.
The item level of the 30 items ranges from 1 to 7, with 1
equaling ‘‘no symptoms,’’ resulting in a total score of 30
points for a patient with no symptoms. Hence before cal-
culating ratios, the scale level has to be changed into a ra-
tio scale by subtracting 30 points.
Unfortunately, this problem is often overlooked, and
therefore, different calculation methods exist: While in
some studies a general subtraction of 30 points has been
applied (eg, Labelle et al9,10), others obviously used the
raw score (eg, Lee and Kim,11 Sacchetti et al,12 Food
and Drug Adminstration13) or at least do not provide in-
formation as to whether the subtraction was carried out
or not (eg, Spina et al,14 Honer et al,15 Breier et al,16
Kane et al17).
Because the different calculation methods might gen-
erate different significance levels, finally resulting in mis-
interpretations of treatment effects, there is a strong need
for clarification on this subject.
Leucht et al6,18 have already emphasized the necessity
of the 30-point subtraction for the calculation of PC.
However, up to now, to the best of our knowledge, no
systematic analysis has been performed to evaluate the
impact of the different usage of PANSS on the results
of schizophrenia studies.
Our aims were therefore (1) to clarify for which statis-
tical procedure it is necessary to subtract the minimum of
30 points and (2) to investigate the effect on study results
if the subtraction was omitted. Specifically, we focused
on conditions which might lead to different results
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concerning significant group effects (eg, treatment
effects), depending on the calculation method used (sub-
tracting or not subtracting 30 points). Hence, we ana-
lyzed test decisions with and without subtraction in (1)
a real data set of a naturalistic follow-up study and (2)
in simulated data.
Patients and Methods
The Database
1. The real data included 400 patients with schizophrenia
spectrum disorder (226 male and 174 female) treated
under naturalistic conditions. Study protocol, main
results, and specific study aims were described in detail
elsewhere.17 The mean age was 35.5 6 11.1 (mean 6
SD) years.
2. To generalize results and to allow detailed analysis of
structural aspects, simulated data sets were included
representing typical data of clinical group trials.
Statistical Analysis
We compared PC and response rates of the real data set
between both calculation methods. In a further step, we
compared test results between both procedures for group
differences regarding percentage of PANSS reduction.
For this purpose, we used linear models with the group-
ing variable as independent variable, focusing on the val-
ues of the test statistics (Wald tests).
Simulated data sets represented results of clinical tri-
als and therefore contain simulated PANSS total at
baseline (PANSS0) and end point (PANSS99), respec-
tively. These data were produced for 2 assumed groups
A and B (representing, eg, placebo vs verum) each in-
cluding 500 patients. For generating simulated baseline
data PANSS0, we used a discrete parametric distribution
which is geared to the empirical distribution of the real
data sets.
To get an impression of a typical treatment course, we
fit a linear model of PANSS99 on PANSS0 for the real
data set. The estimates of this model were used to gener-
ate PANSS99 data for the 2 different subgroups on the
basis of the simulated baseline data. As with this proce-
dure, PANSS99 and PANSS0 would be perfectly corre-
lated (cor = 1); additionally, a Gaussian noise (data
from a normal distribution with l = 0 and a certain r)
was added on PANSS99 to reach a correlation structure
comparable to the real data. The greater the r, the weaker
is the correlation between PANSS99 and PANSS0 and
vice versa. To consider different scenarios, one parameter
of the admission-distribution varied, while all other
parameters remained fixed. For each combination of dis-
tribution parameters, we computed 100 different data
sets and calculated the same statistical measures as for
the real data in each. Accordingly, we averaged over
all data sets with the same parameter combination.
All analyses were performed using the statistical com-
puting environment R 2.8.1.19
Results
Real Data
The real data set consisted of 400 patients treated under
naturalistic conditions with a mean PANSS total at base-
line of 71.17 6 19.14 (mean 6 SD). To demonstrate the
effect of different calculation methods on a test decision,
we arbitrarily chose the grouping variable ‘‘gender.’’
The results presented in table 1 address gender effects
on the treatment course in a naturalistic design. In this
example, the 2 methods obviously lead to different values
of PC, but statistical testing still revealed the same results
concerning the group effect.
Further on, we classified patients as treatment res-
ponders if they reached a specific reduction level from
baseline on PANSS total score in terms of PC (20% or
50% reduction). Table 2 shows z and P values of logistic
regression models, analogue to t values in the Gaussian
linear model above.
In this example, the significance changes between the 2
methods in 1 case: The statistical testing of a possible gen-
der effect using a 20% response criterion leads to contra-
dictory results due to the different calculation methods.
The influence of the calculation method on PC is fur-
ther illustrated in Figure 1. For each individual patient,
Table 1. Real Data set; Group Effect Concerning PC?
Mean PC
Male (%)a
Mean PC
Female (%)a t Valueb P Valueb
30 not subtracted 25.56 26.97 1.82 0.07
30 subtracted 44.38 49.18 1.69 0.09
Note: PC, percent change.
aMean PC in male/female group from baseline to end point.
bTest statistic and P value (Wald test) of the estimated group
effect (male/female) on PC in a linear model.
Table 2. Real Data Set; Group (Gender) Effect Concerning
Response?
20% Response 50% Response
z Value P Valuea z Valuea P Valuea
30 not subtracted 1.64 0.10 0.05 0.96
30 subtracted 2.03 0.04 1.80 0.07
aTest statistic and P value (Wald test) of the estimated group
effect (male/female) on response in a logistic model.
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the difference in PC between the 2 methods is plotted
against the baseline score. Depending on the calculation
method, differences in PC increase with decreasing base-
line level. Hence, a data set with many patients with a low
PANSS at baseline will be more affected than a data set,
where patients have higher scores.
Simulation Study
Wemodeled our simulated data on the previously consid-
ered real data set. With respect to the distribution of the
PANSS0 baseline data, a right skewed (discretized)
gamma distribution was most similar to the real data
set. The relationship between PANSS0 and PANSS99
was established using the parameters of a linear model
on the real data set (an effect between group A and group
B was produced by applying different slope parameters).
The Gaussian noise, added to PNASS99, had a r of 15
and resulted in correlations between PANSS0 and
PANSS99 from 0.39 to 0.59.
Table 3 shows some representative results regarding
PC in the simulation study in relation to different levels
of PANSS0 and in combination with an existing vs a non-
existing effect between groups A and B.
For the same 4 data sets, table 4 shows the correspond-
ing results for the dichotomous outcome, with levels of
20% and 50% for response.
Considering test decisions in simulation studies with-
out real group effect, both methods show the expected
results: Mean t values are close to 0, which is far away
from statistical significance. Nevertheless, the SD of
the t value differences between the 2 methods clearly
increases with decreasing baseline level indicating possi-
ble inconsistencies. When there is a true group effect, dif-
ferences occur especially with low baseline levels.
Regarding PC, the method with subtraction seems to
be more conservative; however, there were also data
where this method showed a higher (absolute) t value.
With regard to responder analyses, it is conspicuous
that with increasing response level and decreasing base-
line level without subtraction of 30 points, the number of
responders is reduced. Although the z values are quite
consistent in studies where no real group effect exists,
results differ clearly for the most other data sets: Without
subtraction, the strong response criterion leads, apart
from the very low responder rates, also to lower (abso-
lute) z values, showing lower significance for the group-
ing variable.
The last column of each table shows the percentage of
simulated studies in which both methods lead to different
conclusions regarding significance. Depending on the
baseline level and the analyzed outcome criteria, the
Fig. 1. Absolute Differences in Percent Changes Between
Calculation Methods Depending on the Baseline Level in a Real
DataSet.With decreasing baseline level, the differences between the
calculation methods increase.
Table 3. Simulation Study; Group Comparison Between A and B With Respect to PC
IDa Effect
Mean PANSS0
b t Valuesc Method Differences
Group A Group B
30 Not
Subtracted 30 Subtracted
SD (t
Difference)d
Significant
Changee
1 No 62.59 62.43 0.14 0.15 0.60 3
2 No 72.53 72.55 0.07 0.03 0.38 1
3 Yes 62.59 62.43 2.41 1.44 0.60 40
4 Yes 72.53 72.55 2.91 2.25 0.39 17
Note: PANSS, Positive and Negative Syndrome Scale; PC, percent change.
aID of simulation study.
bPANSS total: mean at baseline.
cMean t value (Wald tests) of the estimated group effect on PC in a linear model.
dEmpirical SD of differences in t values between both methods (SD(t1  t2)).
eNumber of data sets where the results (Wald tests) differ regarding significance (one method: significant effect found, second method:
no effect found; number of data sets each time: 100).
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number of studies with inconsistent test decisions can rise
to above 50%.
Discussion
Theoretical Implications
Statistics which refer to absolute values of the PANSS are
not affected, regardless of whether 30 points were sub-
tracted or not. By contrast, differences between the 2
scale levels appear when ratios are calculated, as in re-
sponse analyses. A simple numerical example might dem-
onstrate this: Without subtraction, a 50% reduction of
a PANSS baseline level of 50 would result in a score
of 25, which is impossible given the minimum of 30. Fur-
thermore, a 100% reduction is rendered impossible. On
the other hand, the disappearance of all symptoms leads
to a PC of 3050
50
3100= 40%; which does not reflect that
the patient is asymptomatic.
Subtracting 30 points from the PANSS equals a score
with items ranging from 0 to 6 instead of ranging from 1
to 7. This leads to a change in the PANSS level of mea-
surement: Because there is no natural zero point for the
1–7 version, the PANSS in its original version is an ‘‘in-
terval scale’’ on which ratio operations such as calculat-
ing proportions are not suitable,20 as seen in the above
example. The subtraction changes the level of measure-
ment into a ‘‘ratio scale’’ by constructing the zero point.
Using the unchanged interval scale means underesti-
mating PC (in both directions: jPCintervaljjPCratioj),
which leads to the conclusion that the correct calculation
of the PC results in more patients fulfilling response cri-
teria (see tables 1 and 4). Additionally, it results in differ-
ent test statistics (and therefore P values) of statistical
hypothesis tests for group differences, eg, differences be-
tween medications, as shown in this study.
Besides the obvious inequality of the 2 procedures,
quantifying the effect of a wrong calculation is less triv-
ial. In this context, the question arises as to which one is
more likely to reveal a significant difference between
treatment groups. Unfortunately, a general result (
or ) can hardly be obtained because the relation be-
tween both calculation methods follows a nonlinear
function. Nevertheless, according to our simulations,
the following points influencing the statistical outcome
have to be considered:
1. Location and variance of PANSS0 influence the differ-
ence between results of both calculation methods: The
higher the PANSS0, the smaller is the slope of the non-
linear function mentioned. Therefore, with decreasing
level of PANSS0 as well as with increasing variance,
which causes a greater number of lower values, the dif-
ference between calculation methods as well as its var-
iance will increase (see figure 1; tables 3 and 4).
2. Concerning the dichotomous outcome ‘‘response,’’
which is usually defined in terms of a special level
of PC (20%, 30%, .), subtracting 30 points leads to
more patients reaching the response level (table 4).
Apart from this, there is a further important theoret-
ical aspect.
Using the interval version of the scale, a higher re-
sponse level leads to more patients who are not able to
become responders at all: With a 20% criterion, it is im-
possible for patients with an admission score of 37 or
lower to become responders. At a response level of
50%, a baseline score of 59 already precludes a patient
from fulfilling the criteria, which probably affects a rea-
sonable number of patients. In other words, this ap-
proach indirectly excludes a significant number of
Table 4. Simulation Study; Group Comparison Between A and B With Respect to Dichotomous Response
IDa
z Valuesb Ratesc
Significant
Changed
30 Not
Subtracted 30 Subtracted
30 Not
Subtracted 30 Subtracted
Group comparison between A and B with respect to 20% response
1 0.05 0.09 50 66 3
2 0.00 0.12 62 76 6
3 1.93 1.88 47 63 28
4 2.25 2.05 59 73 26
Group comparison between A and B with respect to 50% response
1 0.06 0.01 6 41 8
2 0.15 0.08 10 48 11
3 1.32 2.17 5 38 51
4 2.04 2.15 9 44 32
aID of simulation study.
bMean z value (Wald tests) of the estimated group effect on PC in a logistic model.
cMean responder rates.
dNumber of datasets where the results (Wald tests) differ regarding significance (one method: significant effect found, second method:
no effect found; number of data sets each time: 100).
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patients a priori from end point analysis who might oth-
erwise have fulfilled the criterion.
Implications for Researchers and Clinicians
Results of a study in which PCs were calculated without
a 30-point subtraction (1–7 scale) might be quite different
compared with the (correct) calculation based on the ra-
tio (0–6) scale, even regarding significance. Considering
the 20% response criterion for the presented real data set,
the correct analysis leads to the conclusion that there is
a significant group effect, while an analysis based on the
1–7 scale leads to the opposite result (see table 2). The
results of the simulation study show in some situations
a rate of more than 50% of inconsistent test decisions
(see table 4).
Unfortunately, due to the nonlinearity of the problem,
data provided in standard publications of medication tri-
als are often not sufficient to estimate whether or not
results were affected by the PC calculation method,
and if so, in which direction.
This issue might have concrete and far-reaching impli-
cations as in drug approvals. For example, in some recent
published approval studies of atypical antipsychotics, it
was not clearly stated which method was chosen.16,17 In
at least one, it appears very likely that the wrong proce-
dure might have been used.13 This example illustrates the
high relevance of an international consensus on the
implementation of this issue.
The most straightforward approach with a minimum
source of errors would be a rescaling of the PANSS
from 0 to 6. To avoid the possibility of new uncertainty,
the 0–6 scale could be referred to as ‘‘PANSS (ratio ver-
sion).’’ Using this, little add-on should prevent confound-
ing results from the 2 PANSS versions. At first glance,
this suggestionmay sound extreme, but 2 existing PANSS
versions which are clearly separated by their denotation
will be less confusing and prone to errors than a scale
which forces the researcher to transform it before calcu-
lating PCs and the reader to guess if this transformation
was made or not. Therefore, this solution might help in
avoiding further confusion in the work of schizophrenia
researchers as well as in daily clinical usage.
However, the introduction of a new version (change of
the user manuals, new publication, and new printing)
would cause considerable efforts and might be not
very feasible. An alternative could be the subtraction
of the respective possible minimum prior to any PC anal-
ysis. However, this would implicate that for all PC-
related calculations, eg, the calculation of PC for PANSS
subscores, the correct minimum, depending on the
amount of subscore items needs to be considered. In ad-
dition, a correct description of when and where the sub-
tracted PANSS scores were used and where they were not
would be essential. This in turn bears considerable risks
for errors.
Further discussions appear to be necessary to reach
a broad consensus in the psychiatric community on fu-
ture work with the PANSS. Until this consensus is found,
at least a clear declaration of how the PANSS was used
should be stated in each publication.
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Abstract
Background: The PANSS (Positive and Negative Syndrome Scale) is one of the most important rating instruments
for patients with schizophrenia. Nevertheless, there is a long and ongoing debate in the psychiatric community
regarding its mathematical properties.
All 30 items range from 1 to 7 leading to a minimum total score of 30, implying that the PANSS is an interval
scale. For such interval scales straightforward calculation of relative changes is not appropriate. To calculate
outcome criteria based on a percent change as, e.g., the widely accepted response criterion, the scale has to be
transformed into a ratio scale beforehand. Recent publications have already pointed out the pitfall that ignoring
the scale level (interval vs. ratio scale) leads to a set of mathematical problems, potentially resulting in erroneous
results concerning the efficacy of the treatment.
Methods: A Pubmed search based on the PRISMA statement of the highest-ranked psychiatric journals (search
terms “PANSS” and “response”) was carried out. All articles containing percent changes were included and methods
of percent change calculation were analysed.
Results: This systematic literature research shows that the majority of authors (62%) actually appear to use
incorrect calculations. In most instances the method of calculation was not described in the manuscript.
Conclusions: These alarming results underline the need for standardized procedures for PANSS calculations.
Keywords: PANSS, scale level, literature search
Background
The PANSS is currently the most established scale in
patients with schizophrenia. For example in the high
impact journal “Schizophrenia Bulletin” Kay’s publica-
tion on the Positive and Negative Syndrome Scale
(PANSS) for Schizophrenia is the most frequently cited
article with more than 4000 citations (pubmed 05/2011)
[1]. Despite its common use there still seems to be pro-
found uncertainty within the psychiatric community
regarding its mathematical properties. The pitfall relates
to the calculation of proportions (including percent
changes), which are used in common outcome criteria
like response.
Dichotomized measures such as response can be
understood more intuitively than mean values and are
specifically endorsed by the European Medicines Agency
http://www.ema.europa.eu/htms/human/ich/ichefficacy.
htm.
As pointed out in a previous paper [2], the PANSS is
a 30 item interval scale ranging from 1-7 which implies
that computations of ratios (e.g. percent changes, like
calculation of XX% PANSS reduction from baseline to
final endpoint) are not appropriate. Ignoring this fact
leads to severe mathematical problems, resulting in an
underestimation of the actual response rate and poten-
tially even to erroneous results. Comparing results with
and without PANSS scale level transformation into a
ratio scale revealed that up to 50% of test decisions may
differ [2]. In a comment on this article [3], Leucht et al.
have cited such erroneous calculation methods as one
reason for low response rates in studies on second gen-
eration antipsychotic drugs.
To avoid incorrect calculations the best solution
would be to subtract the theoretical minimum (which is
30 for the total score), resulting in a score range starting
from zero. Percent changes (PCs) have to be calculated
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using this corrected version of the PANSS, which con-
verts the PANSS into a ratio scale. Although Leucht et
al. [4,5] have emphasized this necessity previously, the
uncertainty in the psychiatric community remains.
In our previous report we already cited some articles
performing the correction, as well as some others ignor-
ing the pitfall. These examples also included approval
studies of atypical antipsychotics, where a correct calcu-
lation would seem to be particularly important [6].
However, the mentioned articles were neither represen-
tative, nor did they give any answer to the scope of the
problem. So far, knowledge concerning the relative fre-
quency of incorrectly calculated PANSS PCs has been
limited. If papers with erroneous calculations turn out
to be negligible in comparison to similar publications as
a whole, then most researchers seem to be aware of this
pitfall. If not, we need to open a wider debate on this
issue, because results of studies using different methods
for the calculation of PCs can, strictly speaking, not be
compared.
Thus, the aim of this review article is to further inves-
tigate the scope of incorrect PANSS calculations based
on a systematic review of all articles published in the
top ten journals with the highest impact factors in psy-
chiatry, with a focus on the question: Is the PANSS
used correctly?
Methods
All articles in this review were found by a systematic lit-
erature search in the top-ranked psychiatric journals
using Pubmed http://www.pubmed.com based on the
PRISMA statement [7]. The Impact Factor for psychia-
tric journals according to the 2008 Journal Citation
Reports® Science Edition (Thomson Reuters, 2009) was
used as ranking index. Journals focusing on topics not
related to the PANSS and schizophrenia, such as Mole-
cular Psychiatry or journals specialising in adolescent
psychiatry, were excluded.
Based on these criteria, a predefined Pubmed search
was carried out in the 10 highest-ranked journals enter-
ing the search terms “PANSS” and “response” with no
restrictions regarding date of publication. The search
term “response” was expected to be linked to the calcu-
lation of PCs in the PANSS.
Articles were included if they contained PCs in the
PANSS in any form: Study inclusion criteria as well as
outcome parameters were of interest, as well as continu-
ous PCs and dichotomous response criteria. All articles
containing PCs were included in this review and their
methods of PC calculation were analyzed. The authors
of articles with insufficient method descriptions were
contacted (twice in case of no reply).
A classification was performed independently by two
experienced researchers (MO and FS) into articles with
PC as primary and those with PC as secondary outcome
and into articles using PC as inclusion criteria. In case
of disagreement a third researcher (SM) was consulted
so that all articles could be satisfactorily classified.
Articles grouped according to their PC calculation
method were sub-classified according to their year of
publication, their outcome parameter and their particu-
lar citation number, using nonparametric, rank-based
statistics and corresponding tests.
Results
The ten highest-ranked psychiatric journals according to
their impact factor 2008 included three journals, which
did not fit our search criteria (MOL PSYCHIATR, J
CHILD PSYCHOL PSYC and J AM ACAD CHILD
PSY). These three journals were therefore replaced by
the three subsequent journals on the impact list (PSY-
CHOL MED, J PSYCHIATR RES, J NEUROL NEURO-
SUR). The search in Pubmed in January 2011 resulted
in 68 publications including both terms, “PANSS” and
“response”. Of all articles, 39 actually used PANSS PC
values ([8-46]) and for 33 articles the method of calcula-
tion could finally be determined. Table 1 shows the
main results in detail.
In summary, in at least 62% of all publications (24 out
of 39) the PANSS PC was calculated without the neces-
sary score correction. The PC calculation method was
rarely specified within the text. It was possible only in
seven articles, to deduce the calculation method without
correspondence with the authors: In two articles with
score correction an explanation of the method was
included and in five articles without correction the cal-
culation method could be identified through an exami-
nation of the presented results.
Most of the articles were from the past few years
(median:2007, range:1995-2010), without any noticeable
difference (p = 0.23) between articles with (median:2008,
range:1995-2010) and without score correction (med-
ian:2006.5, range:1998-2010). The number of citations
ranged from 0 to 447 with a median of 18. As with the
year of publication, there was no significant difference
(p = 0.94) regarding the number of citations in the two
groups. There is a significant negative rank correlation
of -0.70 between citation number and publication year
(p < 0.001).
Regarding the outcome classification of the articles, 33
of the 39 articles could be classified concordantly by
researchers MO and FS, and in six cases a third
researcher (SM) was consulted for the final decision. In
twelve of the 39 publications the primary outcome was
based on PC; in five (42%) of these corrected score
values were used, five (42%) used uncorrected scores,
and in two (17%) the method remained unclear. The
majority of the articles found presented PCs as
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secondary outcomes:4 (15%) with correction, 19 (70%)
without, and 4 (15%) articles with unknown status.
There was no significant difference between outcome
classification and method (p = 0.09).
Discussion
The influence of the PC calculation method on the
results of double blind placebo controlled trials has
already been described and quantified in detail in our
previous article [2]. There are two main issues, which
need to be considered: (1) Results of studies without
correction cannot be compared to studies with correc-
tion. A 50% response criterion, for example, denotes
two different facts: With corrected scores it corresponds
to a 50% reduction of the measured symptoms, whereas
without correction it corresponds to a 50% reduction of
the score value, which is something very different. (2)
Results are not only incomparable, but could even lead
to different conclusions: While one method might reveal
a significant treatment effect, the other might lead to
the opposite result [2]. In articles with PC as primary
outcome this is particularly problematic, since without
correction even the main conclusion might be erro-
neous. A special issue in this context are approval stu-
dies, which are obliged to follow guidelines like the
EMEA guidelines and therefore regularly include out-
come measures with PCs. For one approval study [6] an
erroneous calculation of the PANSS PC has already
been shown [2].
In combination with the results of the present review
it becomes even more apparent that there is a strong
need for clarification in terms of the PANSS calculation:
Although some authors use corrected scores, in the
majority of cases the correction is not performed. Most
importantly, the non-awareness of this problem is mir-
rored by the fact that only in two articles the score cor-
rection was described in the Methods section. This
suggests that most researchers conducting schizophrenia
trials are not even aware of this pitfall. Considering the
fact that we probably did not identify all relevant articles
in our literature search by focussing on the searching
term of “response” one could assume that there are
even more publications with incorrect PANSS
calculations.
This is even more remarkable keeping in mind that
the papers reviewed were published in high impact
journals. So we can answer the question posed at the
beginning of this article: Yes, the PANSS is used
incorrectly!
What solutions can be made? First of all, it would be
helpful to recalculate studies which have used the
PANSS PC as primary outcome without correction.
For future work with the PANSS a consensus in the
psychiatric research field is needed: Is it enough to cor-
rect the score every time PCs are used or should the
PANSS be rescaled? Leucht et al., in their comment on
our previous paper, prefer the radical solution: The
PANSS items should be rescaled into a scale ranging
from 0 to 6. This would be the most straightforward
solution and could avoid future problems with PCs.
Additionally, renaming the scale as e.g. “PANSS-0” or
“PANSS (ratio version)”, as suggested previously, could
prevent new confusion, which might otherwise arise
with different scale versions.
Conclusions
Again, we emphasize the necessity of further discussion
and a broad consensus on future action in the psychia-
tric community. Until this is achieved we recommend
that, for PANSS PC calculations, all researchers at least
use the scale correction and include a short statement
in the description of methods.
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Does Clinical Judgment of Baseline Severity and Changes
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Results of a CGI and PANSS Linking Analysis in a Naturalistic Study
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Background: Linking of the Clinical Global Impression (CGI) Scale
and the Positive and Negative Syndrome Scale (PANSS) was performed
within a naturalistic sample. Furthermore, these linking results were
compared with those derived from randomized controlled trials to
examine if the baseline severity might influence the linking results.
Methods: Biweekly PANSS and CGI ratings were performed from
admission to discharge in 398 schizophrenia patients treated within a
naturalistic study. Equipercentile linking was performed using the sta-
tistical program, R 2.8.1. To evaluate how the naturalistic study design
would influence linkage results, a so-called study sample was computed
with patients of the naturalistic study fulfilling common inclusion crite-
ria of randomized controlled trials (n = 199). Patients not fulfilling these
criteria (less ill sample) and those fulfilling the criteria (study sample)
were compared using confidence intervals.
Results: We found a considerable difference between the linking
of the CGI severity score and the PANSS total score comparing the
less ill sample and the study sample. Being considered ‘‘mildly ill’’ at
admission in the less ill sample corresponded to a PANSS total score of
47 points and to a PANSS total score of 67 points in the study sample.
Considering the linking of the CGI improvement score and PANSS
changes, similar results were found for CGI improvement ratings rang-
ing from ‘‘very much improved’’ to ‘‘minimally improved.’’
Conclusions: Despite considerable differences, a 50% PANSS reduc-
tion was found to correspond to a clinical rating of much improved,
which seems to be a suitable definition for response in clinical drug trials.
Key Words: schizophrenia, Positive and Negative Syndrome Scale,
Clinical Global Impression Scale, equipercentile linkage analysis
(J Clin Psychopharmacol 2010;30: 726Y731)
T oday, the clinical implications of the Positive and NegativeSyndrome Scale (PANSS),1 one of the most frequently used
rating scales to assess schizophrenic psychopathology, are not
yet fully understood. To improve the understanding of PANSS
scores and their percentage improvement from a clinical point
of view, corresponding points for simultaneous ratings of the
PANSS and the Clinical Global Impression Scale (CGI) were
analyzed. The CGI is thought to be understood more intuitively
describing the patient’s overall clinical state helping to increase
the understanding of specific PANSS ratings.
However, to this day, predominantly, patients in clinical
pharmaceutical trials requiring inclusion criteria with a pre-
defined minimum symptom severity have been analyzed.1Y3 It
might be hypothesized that this selection bias might increase
corresponding values limiting generalizability with a real-world
situation, which includes patients of all severity grades. It is,
thus, unclear if currently proposed results differ when examining
different patient samples. If PANSS and CGI score would cor-
respond differently depending on the patient sample, this might
have consequences for clinical practice.
Therefore, the aim of the present analysis was to link
the PANSS and the CGI within a naturalistic treatment setting
with broad inclusion and exclusion criteria. In addition, to test
whether the patient sample itself would have an impact on the
linking, these results were compared with an artificial study
sample.
MATERIALS AND METHODS
Subjects and Assessments
Data were collected in a multicenter follow-up program
(German Research Network on Schizophrenia).4 All patients
with the diagnosis of schizophrenia, schizophreniform disorder,
delusional disorder, and schizoaffective disorder according to
the Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV; American Psychiatric Association,
1994) and aged between 18 and 65 years were selected for
inclusion. The exclusion criteria were a head injury, a history
of major medical illness, and alcohol or drug dependency. An
informed written consent had to be provided. The study proto-
col was approved by the local ethics committee. The Positive
and Negative Syndrome Scale (PANSS) for schizophrenia5 and
the Clinical Global Impression Severity Scale (CGI-S)6 were
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applied. The Brief Psychiatric Rating Scale (BPRS) was
extracted from the PANSS to form the study sample. All raters
had been trained using the applied scales. A high inter-rater
reliability was achieved (analysis of variance, intraclass corre-
lation coefficient 9 0.8).
Statistical Analysis
To examine the degree of correlation to perform the
equipercentile linking, the correlations between the CGI and
PANSS were analyzed. To correlate the CGI-S rating and the
PANSS total score, the Spearman correlation coefficient was
applied, and for correlations between the CGI improvement
(CGI-I) score and changes in the PANSS total score, the Pearson
correlation coefficient was applied.
For the present analysis, equipercentile linking was used, a
technique that identifies those scores on both measures that have
the same percentile rank. First, percentile rank functions are
calculated for both measures. Using the percentile rank function
of one variable and the inverse percentile function of the other,
one finds a score on the one variable that has the same percentile
rank for every score of the other variable, respectively. The exact
statistical formula has been described by Kolen and Brennan.7
The linking was performed for the severity scores of the
two scales and for the improvements for each study visit from
baseline biweekly until discharge. To set the improvement or
worsening during the course of treatment in relation to the
psychopathological severity at admission in addition to absolute
changes, percentage changes are also shown. To evaluate if the
study sample itself might influence the linkage results, an arti-
ficial study sample was created out of the naturalistic sample.
To do this, the commonly used inclusion criteria of randomized
controlled trials (RCTs)8Y10 were applied to the whole patient
sample. Patients scoring 4 or higher on the CGI-S score and
concurrently 42 points or more on the BPRSwere included in the
so-called study sample, and patients not fulfilling these criteria
were grouped into a ‘‘less ill sample.’’ The linking of the less ill
sample and the study sample was compared by confidence
intervals using classical nonparametric bootstrap. All statistical
analyses were performed using the statistical program, R2.8 .1.11
RESULTS
Patients
In the entire multicenter study, 474 patients were enrolled.
46 patients had to drop out for different reasons, another
28 patients were excluded because they were discharged from
the hospital within 7 days after admission, and 2 patients were
also excluded because of missing CGI and PANSS values. The
remaining 398 patients participated in the study. The created
study sample consisted of 199 patients achieving a BPRS score
of 42 points or higher and concurrently a CGI-S score of 4
or higher. This study sample featured significantly more male
patients (P = 0.04), worsened significantly less often during
inpatient treatment (P = 0.01) and was significantly less often
treated with an atypical antipsychotic monotherapy (P = 0.04)
FIGURE 1. Linking of CGI-S score and PANSS total score
(whole patient sample).
FIGURE 2. Linking of CGI-I and PANSS percentage changes (whole patient sample).
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compared with patients in the less ill sample also comprising
199 patients.
ASSESSMENTS
PANSS and CGI Correlations
Correlation coefficients between the PANSS total score
and the CGI-S rating were 0.41 for admission, 0.62 for week 2,
0.63 for week 4, 0.62 for week 6, 0.62 for week 8, and 0.60 for
discharge. Correlation coefficients between PANSS changes and
the CGI-I score were 0.58 for week 2, 0.64 for week 4, 0.61
for week 6, 0.59 for week 8, and 0.56 for discharge.
Linking the PANSS Total Score and CGI-S
Within a Naturalistic Sample
Results of the linking between the PANSS total score and
the CGI-S of the less ill sample at admission, weeks 2 to 8, and
discharge are shown in Figure 1. ‘‘Moderately ill’’ on the CGI-S
(= 4) corresponded to a PANSS total score of 47 points at
baseline; 51 points at week 2; 52 points at week 4; 53 points at
week 6; 54 points at week 8; and 56 points at discharge. Being
considered ‘‘markedly ill’’ on the CGI-S (= 5) corresponded to
a PANSS total score of 66 points at admission and week 2;
69 points at weeks 4 and 6; 70 points at week 8; and 72 points
for discharge. A score of ‘‘severely ill’’ on the CGI-S (= 6)
corresponded to a PANSS total score of 84 points at admission;
84.75 points at week 2; 90.50 points at week 4; 85 points at week
6; 87 points at week 8; and 90.25 points at discharge.
Linking the Percentage Change of the PANSS
and CGI-I Within a Naturalistic Sample
The linking between the CGI-I and the percentage PANSS
change from admission to week 2 up to week 8 and discharge
is displayed in Figure 2. Ratings of ‘‘very much improved’’
(CGI-I, 1) corresponded to a percentage PANSS reduction of
84% at weeks 2 and 4 and of 83% at weeks 6 and 8 and at
discharge. Ratings of ‘‘much improved’’ (CGI-I, 2) corre-
sponded to a percentage reduction of 49% at week 2; 54% at
week 4; 52% at week 6; 53% at week 8; and 2% at discharge.
The rating of ‘‘unchanged’’ of the CGI-I scale corresponded to
a percentage increase (equal to worsening) of the PANSS score.
Linking the Absolute Change of the PANSS and
CGI-I Within a Naturalistic Sample
The linking of the CGI-I and the absolute change of the
PANSS is shown in Figure 3. Ratings of very much improved
(CGI-I, 1) corresponded to an absolute PANSS change of 41.25
points at week 2 and 41 points at week 4; 40 points at week 6;
and 39 points at week 8 and at discharge. Ratings of much im-
proved (CGI-I, 2) corresponded to an absolute change of 19 points
at weeks 2 and 4 and 18 points at weeks 6 and 8 and at discharge.
Confidence Intervals to Compare Linking Results
of the Less Ill Sample and Study Sample
& Severity scores (linkage between CGI-S and PANSS total
score)
FIGURE 3. Linking of CGI-I and PANSS absolute changes (whole patient sample).
FIGURE 4. Confidence intervals comparing the linkage of the
CGI-S score and PANSS total score between the less ill sample and
the study sample.
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Both confidence intervals suggest a satisfying goodness
of estimation by featuring rather small distributions (Fig. 4). The
confidence intervals of the 2 different patient samples overlap
not until a CGI-I score of 6. This indicates that the choice of the
sample has a substantial influence of the results of the linking.
& Improvement scores (linkage between CGI-I and percentage
PANSS change)
Confidence intervals were furthermore computed for both
patient samples regarding the improvement scores (Fig. 5). In
the less ill sample, the CGI-I rating of unchanged corresponded
to a percentage worsening of the PANSS at every assessed
time point, whereas in the study sample, the CGI-I rating of
unchanged corresponded to a percentage improvement until
week 8. Starting with the rating of unchanged, the confidence
interval dispersed considerably, mirroring that there were con-
siderably fewer patients with a worsening of symptoms in the
study sample compared with the less ill sample, which explains
the stretched confidence interval of the study sample regarding
the worsening of symptoms.
& Improvement scores (linkage between CGI-I and absolute
PANSS change)
Given that the patients in the study sample featured a higher
PANSS total score at admission, the absolute change of patients
that very much or much improved was found to be considerably
higher than in the less ill sample mirrored in the dispersed
confidence intervals (Fig. 6). Consistent with the linking of
FIGURE 5. Confidence intervals comparing the linkage of the CGI-I score and PANSS percentage change between the less ill sample
and the study sample.
FIGURE 6. Confidence intervals comparing the linkage of the CGI-I score and PANSS absolute change between the less ill sample
and the study sample.
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the percentage improvement diverged confidence intervals were
also found starting with ratings of an unchanged psychopatholo-
gical condition.
DISCUSSION
Linking of a Naturalistic Study Sample
This is the first analysis presenting linking results of the
CGI and the PANSS derived from a naturalistic study reviling
surprisingly rather low PANSS scores to a corresponding CGI
when linking the CGI-S and the PANSS total score. For example,
a CGI-S rating of moderately ill corresponded to a PANSS
total score of 47 points at admission, increasing up to 56 points
at discharge. Because the corresponding PANSS total score
increases with the study duration, this might suggest that the
study registrars rated more stringent with the course of the
study being possibly more tolerant regarding symptom severity
at admission. Another explanation might be that at baseline,
physicians tended to rate the CGI more stringently, allowing
more symptoms at discharge despite rating the patient to have
improved.
When comparing these linkage results to other reports, our
PANSS ratings are almost 30 to 40 points lower in relation to
the corresponding CGI rating.1,3 In our own analysis, a baseline
CGI-S score of moderately ill referred to a PANSS total score of
47 points, whereas in the PANSS and CGI linkage study by, for
example, Leucht et al,1 a CGI-S score of moderately ill corre-
sponded to a PANSS total score of 78 points at baseline. One
explanation for these differing results might lie in the patient
populations analyzed. In the study by Leucht et al, the data
examined included mainly studies with a symptom-severity
inclusion criterion, therefore analyzing at least moderately ill
patients at study entry1 resulting in a mean PANSS total score of
94 T 19 points. In the present naturalistic study, the PANSS mean
score at admission was 71 T 19 points, and the widely differing
mean scores already suggest different linkage results.
Comparing Linking Results of a Naturalistic
Sample to Those of RCTs
By analyzing the confidence intervals, we wanted to dem-
onstrate the difference between the corresponding linkage results
of a naturalistic sample and a study sample derived from RCTs.
The confidence interval for the CGI-S score and the PANSS total
score comparing both study populations shows that the corre-
sponding ratings vary the least regarding severely ill patients,
as the confidence interval covers starting with a CGI rating of
severely ill. This suggests that there is an understanding between
physicians of what a severely ill patient is compared to a patient
with less prominent and less interfering symptoms.
Comparing the linking of the improvement and worsening
scores of our own 2 samples, we found a considerable difference
in CGI-I rating of ‘‘unchanged.’’ For example, a CGI rating of
‘‘unchanged’’ at week 2 corresponded to a worsening in the
PANSS total score by an increase of 11% in the naturalistic
analysis, but the same CGI rating corresponded to a PANSS total
score improvement by 1 percentage point in the study sample. Not
until a patient was rated as ‘‘minimally worse’’ did the PANSS
change correspond to a percentage increase in the study sample.
The results of the study sample are in line with other lit-
erature results of controlled studies1,3 indicating that in rating
acutely symptomatic patients, the rater might expect a relatively
greater improvement to be clinically meaningful. On the other
hand, when a patient has more chronic symptoms, as is often the
case in naturalistic studies, the rater might tolerate a worsening
of symptoms on the PANSS without evaluating this as clinically
meaningful.
However, because there are still differences between com-
parative literature and our own study sample, there seem to be
more influencing factors on linking results as only the baseline
inclusion criteria. One gets the impression that present results
of our less ill sample and our study sample vary by almost 1 point
on the CGI-S score in corresponding PANSS ratings compared
to other link analyses. One explanation might be rater specific.
Present data were assessed in Germany, whereas comparative
studies were often performed in the United States or in other
non-European countries. The association of the cultural back-
ground and rating behavior is a well-known phenomenon in
psychiatry.12
In addition, the statistical procedure of linking should be
kept in mind when discussing the current inconsistency of data.
Because in the link analysis, the PANSS and CGI scores are
examined in a pooled way, meaning that the patient’s individual
corresponding PANSS and CGI rating is broken up, which
seems to be problematic in some cases. For example, a patient
is hearing one voice occasionally telling him to kill himself.
This patient would not score very high on the PANSS scale
because he only hears one voice occasionally; however, clini-
cally, he would probably be rated severely ill, as he is in great
danger regarding suicidal actions. On the other hand, patients
with multiple symptoms scoring high on the PANSS scale might
be able to cope well and continue everyday life being rated
only mildly ill on the CGI scale. In these cases, PANSS and
CGI rating diverge immensely, but in the individual patient,
they are clinically reasonable and meaningful. Taking away
the individual connection of these two ratings as performed in
linking might result in two very dispersing ratings.
Clinical Implications
As demonstrated, different patient populations obviously
lead to different linking results mainly based on different PANSS
and CGI scores at baseline. This result is not very surprising and
has already been expected by Leucht et al1 in one of the first
linking analyses. However, we believe that this is an important
result limiting generalizability of previous linking studies, which
should be kept in mind when interpreting the results of corre-
sponding PANSS and CGI data.
Besides, the varying ratings suggest that there is no inter-
national consensus of PANSS and CGI ratings. In the less ill
sample, the CGI was rated rather strictly in relation to fewer
symptoms on the PANSS scale. Comparative literature data
report this almost the other way around, as several studies found
high PANSS scores with rather moderate CGI scores. However,
maybe an equal and stabile correspondence between these 2
scales is not possible and possibly not necessary. Because the
aforementioned clinical examples on PANSS and CGI ratings
of the patient hearing one voice occasionally telling him to kill
himself or the patient with multiple symptoms underline that
the scales are not synonymous and the correlations are not very
high.13 Therefore, when performing clinical trials, both rating
scales should concurrently be implemented.
In agreement with previous results, we also found a 49% to
50% PANSS total score reduction to correspond to a clinical
status of much improved, which has been found to adequately
mirror response in clinical trials.1,3 This underlines the impor-
tance of implementing a 50% PANSS total score reduction as
standard response criterion in clinical schizophrenia trials find-
ing it to correspond to a clinical measure of much improved in-
dependent of the analyzed study sample.
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Strengths and Limitations
One strength of this study is that it is the first to present
linking results within a naturalistic setting. However, this is only a
small patient sample derived from one study. In addition, because
of the multicenter design, different raters were involved in the
clinical evaluation. Because equipercentile linking assumes the
measurement of the same underlying global trait (ie, global
symptoms), it does not permit an examination of global (CGI) to
individual (PANSS) symptoms.14 Future studies based on a large
database of patients with all degrees of severity in a sufficient
number including the extremes are warranted to contribute further
to the understanding of the PANSS and CGI and their clinical
implications.
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